Geron (NASDAQ:GERN – Get Free Report) and Evogene (NASDAQ:EVGN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.
Risk & Volatility
Geron has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Evogene has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.
Profitability
This table compares Geron and Evogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Geron | -23.04% | -16.29% | -6.82% |
| Evogene | -694.18% | -156.53% | -86.80% |
Valuation and Earnings
This table compares Geron and Evogene”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Geron | $183.88 million | 3.30 | -$83.50 million | ($0.08) | -11.77 |
| Evogene | $3.85 million | 0.89 | -$8.48 million | ($0.91) | -0.43 |
Evogene has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for Geron and Evogene, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Geron | 1 | 2 | 3 | 0 | 2.33 |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
Geron currently has a consensus target price of $3.75, suggesting a potential upside of 298.13%. Given Geron’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Geron is more favorable than Evogene.
Institutional and Insider Ownership
73.7% of Geron shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Geron beats Evogene on 10 of the 13 factors compared between the two stocks.
About Geron
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
About Evogene
Evogene Ltd. is an Israel-based computational biology company founded in 2002. It uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and computational tools, to discover and develop products for agriculture, human health and other life-science applications. The company advances its work through subsidiaries and collaborations. Its businesses have included Casterra, which develops castor seed varieties, and Lavie Bio, which develops microbiome-based agricultural products.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
